CD8A and neoplasm: To test its capability, previous studies reported that human primary CD8+ T cells engineered to express an RR zipCAR (RR leucine zipper motif), with different zipFvs designed to target various tumour antigens, demonstrated specific killing activity when co-cultured with tumour cells expressing the corresponding antigens.